Table 1.
Bestatin-mediated inhibition of HIV-1 cytopathicity
| Bestatin (μg/ml) | Syncytia/well |
Immunofluorescence (% positive cells) |
||||
|---|---|---|---|---|---|---|
| Days post-infection |
||||||
| 3 | 5 | 7 | 3 | 5 | 7 | |
| 0 | 37±1.5 | 95.0±5.5 | 170.0±6.0 | 3.3±0.4 | 25.9±0.4 | 35.5±0.4 |
| 20 | 2±0.4 | 24.0±1.2 | 44.0±0.8 | 1.1±0.2 | 1.0±0.1 | 25.2±0.8 |
| 40 | 0.0 | 18.0±1.6 | 23.0±3.2 | 0.0 | 0.0 | 19.0±0.4 |
| 120 | 0.0 | 7.0±0.6 | 18.0±3.2 | 0.0 | 0.0 | 3.2±0.2 |
Based on the number of cells undergoing syncytia formation as well as on the number of positive immunofluorescent cells, Bestatin decreased HIV-1 infection of HUT78 cells in a dose-response manner.
Each value represents the average of two different experiments, determined in triplicate±S.D. (n=6). Cell treatment with Bestatin for 7 days incubation did not affect cell survival (91.2–94.2%), thymidine incorporation (25.10–26.11 dpm×10−3), and the percent of CD4+ HUT78 cells (88.0–97.3%, in comparison to untreated cells.